drugset / Trial / NCT01339897
A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This Phase 1 study will evaluate multiple doses across a range that has been found to be effective in mouse models of asthma and safe in one Phase 1 clinical trial. It is intended to provide evidence of the tolerability of multiple doses as well as provide information on the Pharmacokinetic (PK) and metabolism of N6022 in humans.
Timeline
- Start
- 2011-04
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | N6022 | Small molecule | 5 mg | Intravenous |
| Comparator | N6022 | Small molecule | 10 mg | Intravenous |
| Comparator | N6022 | Small molecule | 20 mg | Intravenous |
Indications
No indication recorded.